Sugi Predict

Sugi Predict / Compounds / SCHEMBL4584929

SCHEMBL4584929

SCHEMBL4584929

CSc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccnc(Oc4ccccc4)n3)[nH]2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 17/20 0.56
▸ MAPK13 O15264 7/20 0.56
▸ MAPK12 P53778 7/20 0.56
▸ MAPK11 Q15759 7/20 0.56
▸ ALOX5 P09917 4/20 0.56
▸ GCGR P47871 4/20 0.56
▸ CSNK1D P48730 3/20 0.56
▸ MAPK9 P45984 3/20 0.56
▸ PRKD3 O94806 1/20 0.56
▸ MAP4K4 O95819 1/20 0.56
▸ LCK P06239 1/20 0.56
▸ RET P07949 1/20 0.56
▸ PRKACA P17612 1/20 0.56
▸ RPS6KB1 P23443 1/20 0.56
▸ MATK P42679 1/20 0.56
▸ FRK P42685 1/20 0.56
▸ CSNK1A1 P48729 1/20 0.56
▸ GSK3A P49840 1/20 0.56
▸ GSK3B P49841 1/20 0.56
▸ CSNK1G2 P78368 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4586510 0.87 MAPK14 (0.61) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL7201822 0.85 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL4584148 0.84 ALOX5 (0.58) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL7209158 0.82 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL7805607 0.80 MAPK14 (0.49) MAPK14MAPTL3MBTL1
SCHEMBL7202369 0.79 MAPT (0.41) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL4584932 0.79 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL4974887 0.79 MAPK14 (0.81) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL4553291 0.77 MAPK14 (0.72) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL8120061 0.77 MAPK14 (0.55) MAPK14MAPK13MAPK12MAPK11CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610695-B1 Prophylaxis or treatment of CSBP/RK/p38 kinase mediated disease SMITHKLINE BEECHAM CORPORATION 2003-08-26 — — US claimed
EP-1545535-A4 TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE SCIOS INC (US) 2008-06-04 — — EP disclosed
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS PROTTER ANDREW A 2008-05-08 — — US disclosed
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase PROTTER ANDREW A 2008-02-14 — — US disclosed
US-7268139-B2 Methods of promoting osteogenesis SCIOS, INC. (US) 2007-09-11 — — US disclosed
US-7244441-B2 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. (US) 2007-07-17 — — US disclosed
EP-1676574-A2 Methods for promoting survival of transplanted tissues and cells Johnson & Johnson Vision Care, Inc. (US) 2006-07-05 — — EP disclosed
US-20060019971-A1 Treatment of cardiovascular disease with inhibitors of p38 kinase SCIOS INC. 2006-01-26 — — US disclosed
EP-1545535-A2 TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE SCIOS INC. (US) 2005-06-29 — — EP disclosed
US-20050129729-A1 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. 2005-06-16 — — US disclosed
US-20040171659-A1 Methods for treating diabetes SCIOS, INC. 2004-09-02 — — US disclosed
US-20040162289-A1 Methods of promoting osteogenesis UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY 2004-08-19 — — US disclosed
WO-2004019873-A9 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC (US) 2004-06-24 — — WO disclosed
US-20040122008-A1 Treatment of pain by inhibition of p38 MAP kinase SCIOS, INC. 2004-06-24 — — US disclosed
WO-2004024083-A2 METHODS OF BONE HEALING UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2004-03-25 — — WO disclosed
WO-2004021988-A2 TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE SCIOS INC. (US) 2004-03-18 — — WO disclosed
US-6610695-B1 Prophylaxis or treatment of CSBP/RK/p38 kinase mediated disease SMITHKLINE BEECHAM CORPORATION 2003-08-26 — — US disclosed
EP-0994870-A4 NOVEL ARYLOXY SUBSTITUTED PYRIMIDINE IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM (US) 2002-10-23 — — EP disclosed
EP-0994870-A1 NOVEL ARYLOXY SUBSTITUTED PYRIMIDINE IMIDAZOLE COMPOUNDS Smithkline Beecham (US) 2000-04-26 — — EP disclosed
WO-1998057966-A1 NOVEL ARYLOXY SUBSTITUTED PYRIMIDINE IMIDAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1998-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019971-A1 Treatment of cardiovascular disease with inhibitors of p38 kinase MAPKAPK5, MAPK1, MAPKAPK2 MAPK14 36/4885MAPK13 34/4885MAPK12 27/4885
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS MAPK1, BMP2, MAPK3 MAPK14 23/4885MAPK13 15/4885MAPK12 30/4885
US-20040162289-A1 Methods of promoting osteogenesis MAPK1, BMP2, MAPK3 MAPK14 23/4885MAPK13 15/4885MAPK12 30/4885
US-20040122008-A1 Treatment of pain by inhibition of p38 MAP kinase OPRK1, OPRL1, MAPK3 MAPK14 36/4885MAPK13 39/4885MAPK12 28/4885
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase OPRK1, OPRL1, MAPK3 MAPK14 36/4885MAPK13 39/4885MAPK12 28/4885
US-20040171659-A1 Methods for treating diabetes SLC5A2, MAPK4, MAPK3 MAPK14 53/4885MAPK13 46/4885MAPK12 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.